StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX – Get Free Report) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Athersys Stock Performance
Shares of NASDAQ ATHX opened at $0.01 on Wednesday. The company has a market cap of $372,782.76, a price-to-earnings ratio of 0.00 and a beta of -0.90. Athersys has a 12 month low of $0.01 and a 12 month high of $1.99. The stock has a 50-day moving average price of $0.01 and a two-hundred day moving average price of $0.07.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp increased its stake in shares of Athersys by 45.2% in the first quarter. State Street Corp now owns 42,413 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 13,200 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Athersys by 5.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 575,537 shares of the biopharmaceutical company’s stock valued at $349,000 after buying an additional 30,249 shares during the period. CIBC Asset Management Inc acquired a new position in shares of Athersys in the first quarter valued at approximately $45,000. Renaissance Technologies LLC increased its stake in shares of Athersys by 67.3% in the fourth quarter. Renaissance Technologies LLC now owns 99,936 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 40,200 shares during the period. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Athersys during the 4th quarter valued at approximately $36,000. Institutional investors and hedge funds own 19.35% of the company’s stock.
About Athersys
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Featured Articles
- Five stocks we like better than Athersys
- What to Know About Investing in Penny Stocks
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What Does a Stock Split Mean?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Dividend Capture Strategy: What You Need to Know
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.
